DSP Healthcare Fund delivered a 15.7% return over the past three months, outperforming peers like SBI Healthcare Opportunities and ICICI Prudential Pharma Healthcare & Diagnostics Fund. While the fund has shown strong short-term gains as of June 25, 2026, leadership in sectoral mutual funds often shifts with market cycles. Investors may need to evaluate performance across multiple time frames to gauge consistency.
What Happened
DSP Healthcare Fund has ranked first among pharmaceutical and healthcare sectoral mutual funds for the three-month period ending June 25, 2026. According to data from ACE MF, the fund recorded a return of 15.7% during this period. This performance places it ahead of notable competitors in the category, including SBI Healthcare Opportunities Fund, which returned 14.4%, and ICICI Prudential Pharma Healthcare & Diagnostics Fund, which delivered 13.4%. These rankings specifically track funds with assets under management exceeding ₹1,500 crore.
Why Performance Leadership Shifts
The leadership in thematic and sectoral funds, such as those focused on healthcare, often changes depending on the time frame measured. While DSP Healthcare Fund leads in the three-month window, other funds have shown stronger performance over longer durations. For instance, SBI Healthcare Opportunities Fund has been the top performer over the six-month and one-year periods, with gains of 14.5% and 14.6% respectively.
Similarly, when extending the view to a three-year horizon, ICICI Prudential Pharma Healthcare & Diagnostics Fund has led the category with a 26.4% return. Other funds like Nippon India Pharma Fund and Mirae Asset Healthcare Fund also maintain significant positions in the sector, with Nippon India holding the largest assets under management among the top five at ₹8,635.7 crore, followed by Mirae Asset Healthcare Fund at ₹3,090.5 crore.
Understanding Sectoral Fund Risks
Sector-specific mutual funds, like those dedicated to the healthcare and pharmaceutical industry, carry different risks compared to diversified equity funds. Because these funds invest almost exclusively in one sector, their performance is closely tied to industry-specific events, such as regulatory changes, global drug pricing trends, or changes in healthcare policy.
This concentration can lead to higher volatility. A fund may perform exceptionally well during a cyclical upturn in the pharma sector but could face steeper declines if that sector falls out of favor. Consequently, a high return over a short period, such as three months, does not guarantee similar results in the future. The data shows that even funds with strong track records can experience periods where they lag behind their sector peers.
Benchmark And Consistency
Beyond short-term rankings, consistent performance relative to a benchmark is another metric often tracked by investors. DSP Healthcare Fund has shown the ability to outperform its benchmark, recording 14.9 percentage points above the benchmark over a one-year period, whereas the benchmark itself saw a negative return of -3.5%. Over a three-year period, the fund also exceeded its benchmark by 12.2 percentage points.
What To Monitor
Investors tracking these funds often look beyond the recent quarterly ranking. Key monitorables include the fund's long-term consistency across different market cycles, the volatility of the specific pharmaceutical sub-sectors the fund holds, and the overall management strategy. Evaluating a fund's performance over three-year or five-year periods often provides a clearer picture of how it handles different market phases compared to looking only at a three-month snapshot.